Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer

• Aurora Rodríguez Pérez ^[1] ; Enriqueta Felip Font ^[9] ; Rodolfo Chicas-Sett ^[10] ; Ángel Montero-Luis ^[2] ; Laura de Paz Arias ^[3] ; Aránzazu González-del-Alba ^[4] ; Fernando López-Campos ^[5] ; Carlos López López ^[6] ; Ovidio Hernando Requejo ^[2] ; Antonio José Conde-Moreno ^[11] ; José Ángel Arranz Arija ^[7] ; Javier de Castro Carpeño ^[8]
  1. [1] Hospital Ruber Internacional

     Hospital Ruber Internacional

     Madrid, España

     
  2. [2] Hospital Universitario HM Sanchinarro

     Hospital Universitario HM Sanchinarro

     Madrid, España

     
  3. [3] Complexo Hospitalario Universitario de Ferrol

     Complexo Hospitalario Universitario de Ferrol

     Ferrol, España

     
  4. [4] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  5. [5] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  6. [6] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  7. [7] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  8. [8] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  9. [9] Departamento de Oncología Médica, Hospital Universitario del Vall d’Hebron, Barcelona, España
  10. [10] Departamento de Oncología Radioterápica, ASCIRES Grupo Biomédico, Valencia, España
  11. [11] Servicio de Oncología Radioterápica, Hospital La Fe, Valencia, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 4 (April), 2023, págs. 882-896
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Oligometastatic disease (OMD) defines a cancer status that is intermediate between localized and widely spread metastatic disease, and can be treated with curative intent. While diagnostic imaging tools have considerably improved in recent years, unidentified micrometastases can still evade current detection techniques, allowing the disease to progress. The various OMD scenarios are mainly defined by the number of metastases, the biological and molecular tumour profiles, and the timing of the development of metastases. Increasing knowledge has contributed to the earlier and improved detection of OMD, underlining the importance of early disease control. In view of increasing OMD detection rates in current real-world clinical practice and the lack of standardized evidence-based guidelines to treat this cancer status, a board of experts from the Spanish Societies of Radiation Oncology (SEOR) and Medical Oncology (SEOM) organized a series of sessions to update the current state-of-the-art on OMD from a multidisciplinary perspective, and to discuss how results from clinical studies might translate into promising treatment options. This expert review series summarizes what is known and what it is pending clarification in the context of OMD in the scenarios of non-small cell lung cancer and breast cancer (Part I), and prostate cancer and colorectal cancer (Part II), aiming to offer specialists a pragmatic framework to help improve patient management.